Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications <a href="https://www.researchtopractice.com/FirstLineTherapyALKmNSCLC24" rel="noopener noreferrer" target="_blank">here</a>.

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer.&nbsp;CME information and select publications <a href="https://www.researchtopractice.com/FirstLineTherapyALKmNSCLC24" rel="noopener noreferrer">here</a>.

First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Share First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

Sign up to save your podcasts

First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor

First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor